Condition
Local Progression or Metastatic Melanoma With Failed First-line Treatment
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Zkab001 Monotherapy
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Unknown1
Clinical Trials (1)
Research Network
Common Treatments
- Zkab001 Monotherapy1
- Pexavec Combined With Zkab0011
Active Sponsors
- Lee's Pharmaceutical Limited1